Learnings from Oncology Development Experience that May Help T-Cell Engager Development in Autoimmune Diseases
- Utilizing oncology datasets to inform autoimmune development strategies, dose selection, and overall risk mitigation
- Taking advantage of safety, pharmacokinetic, pharmacodynamic, and dose selection Oncology learnings
- Designing oncology studies with future autoimmune applications in mind by incorporating relevant translational endpoints, immune monitoring strategies, and site selection frameworks